The Board of Bactiguard Holding AB (publ) ("Bactiguard") announced that current CEO Anders Göransson will step down as CEO to enter a new role as Global Head of Licensing and Executive Vice President. The Board has, in view of this, appointed the Chair of the Board Thomas von Koch as interim CEO. Vice Chair of the Board Christian Kinch assumes the role of non-executive Chair for the period during which Thomas von Koch is unable to be Chair due to the interim CEO position.

Anders Göransson joined Bactiguard in October 2021 with the objective to formulate a comprehensive long-term strategy and sharpen internal processes. Over the course of one and a half years with the company, these objectives have been accomplished. Bactiguard has a clear growth strategy and five well defined therapeutic areas.

In addition, two long-term financial goals have been defined, to achieve revenues of 1 billion and an EBITDA of SEK 400 million by 2026. With the new growth-focused strategy in place, Bactiguard enters a new phase of the company's development, to build both an even stronger license business and enter the US. Bactiguard is also on a transformation journey, from being a medical device company to a medtech business.

This shift demands additional leadership skills to accelerate the journey, for instance from digital disruption and internationalization.